Skip to main content
TipRanks
Go Ultimate75% OFF

Resverlogix (0VF9) Share Price & Analysis

0 Followers

0VF9 Stock Chart & Stats

CA$0.10CA$0.00(0.00%)
At close: 4:30 PM GMT
C$0.1C$0.2C$0.3Apr 4Mar 8Feb 13Feb 27
Day’s Range
CAD 0.09 - CAD 0.10
52-Week Range
CAD 0.09 - CAD 0.12
Previous Close
CAD 0.10
Volume
N/A
Average Volume (3M)
0
Market Cap
CAD 25.82M
Enterprise Value
CAD 141.04M
Total Cash (Recent Filing)
CAD 156.99K
Total Debt (Recent Filing)
CAD 77.18M
Price to Earnings (P/E)
―
Beta
1.30
Next Earnings
Apr 05, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Focused Epigenetic Drug Platform

A defined focus on small-molecule epigenetic therapies gives Resverlogix a coherent development strategy and concentrates resources around related cardiovascular and metabolic applications. This specialization could support cumulative scientific and intellectual-property value as programs advance.

Cash Flow Tracks Reported Losses

Free cash flow closely tracking net loss indicates that reported losses are largely reflected in actual cash consumption rather than being driven primarily by large non-cash charges. That alignment improves the transparency of financial performance and cash needs.

Recent Free Cash Flow Improvement

The reported improvement in free cash flow versus 2025 suggests some progress in moderating cash consumption, even though the company remains cash-burning. If sustained, better cash-flow performance could modestly extend funding capacity and reduce pressure on future financing.

Bears Say

No Revenue And Worsening Losses

ไม่มี revenue leaves Resverlogix without operating income to fund research, while the larger TTM loss shows profitability has deteriorated. Continued negative EBIT and EBITDA limit operating leverage and make progress dependent on successful development or external financing.

Severely Leveraged Balance Sheet

Deeply negative equity and debt that greatly exceeds the asset base indicate a very thin financial cushion. This structure heightens refinancing and solvency risk, reduces flexibility to absorb setbacks, and can constrain investment in clinical development or commercialization.

Persistent Cash Funding Requirement

Negative operating and free cash flow show that the business currently consumes cash rather than funding itself. Persistent burn increases dependence on financing, while the fragile balance sheet may make raising or refinancing capital more difficult over the next several quarters.

Resverlogix News

0VF9 FAQ

What was Resverlogix’s price range in the past 12 months?
Resverlogix lowest share price was C$0.09 and its highest was C$0.12 in the past 12 months.
What is Resverlogix’s market cap?
Resverlogix’s market cap is C$25.82M.
When is Resverlogix’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Resverlogix’s earnings last quarter?
Resverlogix released its earnings results on Nov 13, 2026. The company reported -C$0.003 earnings per share for the quarter.
Is Resverlogix overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Resverlogix pay dividends?
Resverlogix does not currently pay dividends.
What is Resverlogix’s EPS estimate?
Resverlogix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix have?
Resverlogix has 344,286,700 shares outstanding.
What happened to Resverlogix’s price movement after its last earnings report?
Resverlogix reported an EPS of -C$0.003 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Resverlogix?
Currently, no hedge funds are holding shares in GB:0VF9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology